Business
Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease
NEW YORK, Aug. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, Aug. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model.\n\n \n \n \n \n \n \n\n \nThe goal of the study is to determine the effects of HT-ALZ on behavioral and pathological markers of Alzheimer's disease and to determine if HT-ALZ can improve learning and memory in an animal model of Alzheimer's disease. Hoth study will also determine if behavior is improved utilizing HT-ALZ in blocking NK-1Rs. To evaluate other forms of memory, we will also determine if chronic HT-ALZ treatment influences non-spatial memory using a novel object recognition and novel object location task. These tests will give us the ability to assess both hippocampal and non-hippocampal dependent memory. Additionally, these tests do not require food or water deprivation to motivate the animals, which may interfere with drug delivery or dosing regulation over time.\nThe designed studies are taking place under a Scientific Research Agreement entered by Hoth as of June of this year.\nAbout Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/\nForward-Looking StatementThis press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candi...